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Abstract
Mucopolysaccharidosis type I (MPS I) is a rare lysosomal disorder caused by deficiency of alpha-L-iduronidase. Few
clinical trials have assessed the effect of enzyme replacement therapy (ERT) for this condition. We conducted an ex-
ploratory, open-label, non-randomized, multicenter cohort study of patients with MPS I. Data were collected from
questionnaires completed by attending physicians at the time of diagnosis (T1; n = 34) and at a median time of 2.5
years later (T2; n = 24/34). The 24 patients for whom data were available at T2 were allocated into groups: A, no ERT
(9 patients; median age at T1 = 36 months; 6 with severe phenotype); B, on ERT (15 patients; median age at T1 = 33
months; 4 with severe phenotype). For all variables in which there was no between-group difference at baseline, a
delta of   20% was considered clinically relevant. The following clinically relevant differences were identified in
group B in T2: lower rates of mortality and reported hospitalization for respiratory infection; lower frequency of
hepatosplenomegaly; increased reported rates of obstructive sleep apnea syndrome and hearing loss; and stabiliza-
tion of gibbus deformity. These changes could be due to the effect of ERT or of other therapies which have also been
found more frequently in group B. Our findings suggest MPS I patients on ERT also receive a better overall care. ERT
may have a positive effect on respiratory morbidity and overall mortality in patients with MPS I. Additional studies fo-
cusing on these outcomes and on other therapies should be performed.
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Introduction
Mucopolysaccharidoses (MPS) constitute a group of
lysosomal disorders caused by 11 distinct enzyme deficien-
cies. In mucopolysaccharidosis type I (MPS I; OMIM
607014, 607015 e 607016), deficient activity of the enzyme
alpha-L-iduronidase (EC 3.2.1.76) leads to incomplete
cleavage of the glycosaminoglycans dermatan and heparan
sulfate, which build up in several organ systems: respira-
tory, nervous, musculoskeletal, gastrointestinal (spleen and
liver), and cardiovascular. Patients are affected to varying
degrees and have a shortened life expectancy (Neufeld and
Muenzer, 2001). From a clinical standpoint, MPS I may be
divided into two phenotypes: severe, with major mental
disability, and attenuated, with little or no cognitive impair-
ment. Nevertheless, these subtypes are merely extremes of
a continuous spectrum of the same condition, and there are
clinical heterogeneity even within the subgroup (Moore et
al., 2008).
Prevalence estimates of MPS I have varied widely
among studies, ranging from 0.69 to 1.66 per 100,000 pop-
ulation (Lowry et al., 1990, Nelson, 1997; Meikle et al.,
1999; Baehner et al., 2005; Moore et al., 2008; Boy et al.,
2011); global data suggest the severe phenotype is the most
common phenotype found (Nelson, 1997; Moore et al.,
2008). However, a recent study suggests that attenuated
phenotype is the most prevalent in Latin America (Muñoz-
Rojas et al., 2011).
Management of patients with MPS I involves a multi-
disciplinary team of experts (Neufeld and Muenzer, 2001;
Pastores and Meere, 2005; Pastores et al., 2007, 2008;
Muenzer et al., 2009; Turra and Schwartz, 2009), and in-
cludes therapeutical strategies such as hematopoietic stem
cell transplantation (HSCT) and enzyme replacement ther-
apy (ERT) with Laronidase, a polymorphic variant of the
human enzyme alpha-L-iduronidase produced by DNA re-
combinant technology in CHO (chinese hamster ovary)
cells. HSCT is indicated mainly for patients under 2 years
old who present Intelligence Quotient (IQ) over 70 (Muen-
zer et al., 2009; Giugliani et al., 2010b). Laronidase is usu-
ally indicated for symptomatic patients of any age and who
present at least one clinical manifestation that is known to
be improved with ERT (Muenzer et al., 2009; Giugliani et
al., 2010a,b). Laronidase was approved by the Food and
Drug Administration (FDA) and European Medicines
Agency (EMA) in 2003, and by the Brazilian counterpart
(ANVISA) in 2005. Patients for whom ERT is indicated
should receive it weekly and indefinitely. However, several
doubts remain as to the efficacy of this therapy (Kakkis et
al., 2001; Sifuentes et al., 2007; Wraith et al., 2007; Clarke
et al., 2009).
Currently in Brazil, there are no public policies for
MPS disorders, and even the tests necessary for diagnosis
are not availabe through the public health system. There-
fore, in 2004, the Brazilian MPS Network (Rede MPS
Brasil) was established. It is an integrated network of Bra-
zilian genetics centers designed to facilitate community ac-
cess to diagnostic modalities and provide information on
the management and treatment of MPS. The Network pro-
vides diagnostic services as requested, requiring only that
samples submitted for analysis be accompanied by a signed
informed consent form (obligatory) and by a completed
standardized form containing clinical information on the
patient (optional), which are available online at
http://www.ufrgs.br/redempsbrasil/documentos/ficha_regi
stro_pt_br.pdf. From 2004 through July 2009, the MPS
Network diagnosed 83 Brazilian patients with MPS I.
The objective of the present work was to identify clin-
ical outcomes of ERT for MPSI, in order to establish its real
benefits to patients, and to develop a better panorama of
ERT for MPSI in Brazil
Subjects and Methods
This was an exploratory, open-label, non-rando-
mized, multicenter cohort study of patients with MPS I di-
agnosed by the MPS Brazil Network (Rede MPS Brasil).
The study was approved by the Hospital de Clínicas de
Porto Alegre (HCPA) Research Ethics Committee, and cur-
rent standards for Good Clinical Practice were followed
throughout.
Between 2004 and 2009, completed standardized
clinical forms from MPS Network were only submitted for
34/83 Brazilian patients. Data collected from these forms
constituted the baseline dataset for patients included in this
study at the time of diagnosis (time point 1, T1).
The physicians in charge of care of each of these 34
patients were invited to complete a second form which
comprised the follow-up dataset for the purposes of this
study (time point 2, T2, a median time of 2.5 years after
T1). This form was similar to the first, except for including
additional questions regarding concomitant therapies (type,
frequency, etc.). Overall, the physicians of 24 patients com-
plied with this request. The 10 patients for whom T2 data
was not available were not included in the comparative
analysis.
At T2, patient charts were divided into two groups:
Group A (n = 9) comprised patients who had not been on
ERT, whereas Group B (n = 15) comprised patients who
were on ERT. The criterion for subjecting patients to ERT
was the physician’s treatment choice based on the details of
each case, which were not available for analysis.
The severity of the clinical phenotype (severe or at-
tenuated) was defined as per the attending physician’s im-
pression of the neurological involvement/cognitive status
of the patient (severe = abnormal; attenuated = normal).
Age at diagnosis was defined as the age at the time of col-
lection of the sample sent for analysis at T1. For patients
who died during the study period, the last data available
were used for analysis.
Data were entered into a Microsoft Excel spread-
sheet. Categorical variables were expressed as absolute and
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relative frequencies. Normally distributed continuous vari-
ables were expressed as means and standard deviations,
whereas asymmetrically distributed continuous variables
were expressed as medians and interquartile ranges (IQR).
Kaplan-Meier estimates were used for survival analysis.
Comparative analysis was limited to patients for
whom both assessments (T1 and T2) were available and to
variables for which data were available at T1 and T2 in at
least 60% of patients, namely: physical examination find-
ings (anthropometric parameters, presence of joint contrac-
tures, hepatosplenomegaly, corneal opacities, and gibbus
deformity); developmental delay (specified as language de-
lay, motor delay, and sphincter control delay); history of
seizures; chronic medication use; death; history of surgical
procedures; history of and reason for hospital admissions;
and reported presence of sleep apnea and hearing loss.
As defined a priori by the authors, a difference of
 20% between Groups A and B at T1 (B-A) and a delta of
  20% between Groups A and B at T2 as compared with
T1 [delta% = (%T2 in Group B - %T1 in Group B) - (%T2
in Group A - %T1 in Group A)] were considered clinically
relevant. This cuttoff is conservative and was established
after a consensus meeting based on the borderline effect of
Laronidase in the improvement of Forced Vital Capacity
(about 10%), which is considered clinically relevant
(Wraith et al., 2004), as well as in the absence of other ob-
jectives parameters to define clinical relevancy in this dis-
order. Clinical improvement was defined as a delta of
 -20% between groups. In patients who met this criterion
for clinical improvement, disease was considered stable
when there were no changes between T1 and T2 in Group
B, but only in Group A. Clinical deterioration was defined
as a delta of  +20% between groups. For parameters in
which a clinically significant between-group difference
was already present at baseline (T1), the delta required for
determination of clinical relevance on comparison between
T2 and T1 was increased to  40%. These criteria were
adopted due to the exploratory nature of the study and to the
small sample size, which precluded formal statistical as-
sessment.
Results
Overall sample (T1; n = 34)
Thirty-four Brazilian patients with MPS I (32 unre-
lated families) were included in the study. Parental consan-
guinity was present in eight of the 32 families (25%). Of the
34 patients, 17 were from the Southeast region of Brazil,
eight from the Northeast, seven from the South and two
from the North of the country. Sixteen patients were male
(47%), and median age at enrollment was 4.1 years (range,
10.4 months-38.1 years; IQR, 18-118 months). There was
substantial heterogeneity in presenting symptoms, which
included gibbus deformity (n = 10), articular complaints
(n = 8), hepatosplenomegaly (n = 5), hernia (n = 5), and
respiratory tract infections (n = 5). The median age at
symptom onset was 8.5 months (range, 0-120 months; IQR,
3.75-27 months). Twenty-four patients exhibited their first
symptoms of MPS I during the first year of life; nine experi-
enced symptom onset between the ages of 1 and 5 years,
and one patient experienced symptom onset at age 10.
Seven patients died between T1 and T2: five with the
severe form of MPS I (four off ERT, one on ERT) and two
with the attenuated phenotype (one off ERT, one on ERT)
(Table 1). Overall, at 2.5 years of follow-up after diagnosis,
17 of the 24 patients (70.5%) who completed T1 and T2 as-
sessment were alive, with only five of having the severe
phenotype.
Baseline profile of Groups A and B (n = 24)
Patients from Groups A (n = 9) and B (n = 15) at T1
are described in Tables 2 and 3. Groups A and B were dis-
similar at T1: the severe phenotype of MPS I was more
common in Group A, whereas hepatomegaly, a history of
hernia repair, and hospitalization for lower respiratory tract
infections (LRTI) were more common in Group B, as
shown in Table 3. No patient from group B underwent
HSCT, while one patient from group A has been submitted
to this procedure (Table 1), and for him, the data was col-
lected up to the moment of the procedure.
Profile of Groups A and B at T2 (Table 3, n = 24)
Median age at onset of ERT was 50.8 months (IQR,
16-247 months), 17.8 months after diagnosis. There was a
difference between Groups A and B regarding the median
time elapsed between T1 and T2 (Group A, 11 months;
Group B, 41 months). Kaplan-Meier analysis showed that
the likelihood of survival at 7 years after symptom onset
was 41.7% in Group A vs. 83.9% in Group B. Median dura-
tion of ERT was 3 years (IQR, 1.6-3.6 years). Median age at
T2 was 76 months (6 years) in Group A and 86 months
(7 years) in Group B.
Concomitant interventions
Patients also received other interventions during the
study. Most drugs were prescribed for cardiovascular and
ophthalmic complaints, and vitamin supplements were also
common (Table 3). Other therapies, which were found to be
more common in Group B than in Group A in T2, included
physical therapy, speech therapy, hydrotherapy, and occu-
pational therapy (data not shown).
Discussion
This is an exploratory, retrospective study of a cohort
of patients who present a rare disorder (MPS I) treated
through a novel therapy (ERT with Laronidase). Its main
limitations are the relatively small sample size, the method
we used for data collection (a retrospective filling out, by
the attending physician, of a relatively long questionnaire)
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and the clinical heterogeneity between the groups which re-
ceived or not ERT. The discrepancies between the two
groups regarding the prevalence of the severe form of the
disease prevent us from drawing stronger conclusions re-
garding the effect of ERT. Unfortunaly, due to the small
sample size, we were not able to perform certain important
subgroup analyses, such as the follow-up per phenotype,
which could have added useful information to our work.
Even so, we have been able to generate some interesting
new data on the issue.
The inclusion of ERT in routine treatment regimens
for MPS I is still recent practice in Brazil (Giugliani et al.,
2010a). Nevertheless, the proportion of patients on ERT in
this study (62.5%) was similar to that reported in previous
studies conducted in the country (78% and 88% respec-
tively) (Turra and Schwartz, 2009; Boy et al., 2011). Re-
garding indications for HSCT, due to the logistical and
clinical challenges posed by this procedure in Brazil or by
delayed diagnosis of MPS I in Latin America (Giugliani et
al., 2010b; Muñoz-Rojas et al., 2011), few patients appear
to pursue it as a treatment modality, although it is the
first-line therapy of choice for young children with the se-
vere phenotype.
The earlier median age at diagnosis in our sample (49
months) as compared with that reported by another Brazil-
ian study (72 months) (Vieira et al., 2008) may have been
associated with greater awareness of MPS I by the Brazil-
ian physicians, and to the establishment of the MPS Net-
work. Nevertheless, diagnosis is still delayed, as the vast
majority of patients exhibited symptoms as early as the first
year of life. The symptoms presented and the age at symp-
tom onset were consistent with previous reports (Vijay and
Wraith, 2005; Vieira et al., 2008). The presence of early
clinical manifestations in the first year of life is associated
with the severe form of MPS I, as reported elsewhere
(Pastores et al., 2007; Vieira et al., 2008). Although the se-
vere form of MPS I is the most frequent one considering
worldwide data (Nelson, 1997; Moore et al., 2008; Mu-
ñoz-Rojas et al., 2011), our sample was mostly composed
of patients with the attenuated phenotype (60%), as is to be
expected in Latin America (Muñoz-Rojas et al., 2011).
Mean survival was longer than previously described
(Moore et al., 2008), which may be attributed, at least
partly, to duration of ERT and to the greater prevalence of
patients with the attenuated phenotype in our sample. Nev-
ertheless, some patients died at an early age, possibly due to
marked vital-organ involvement or to absence or insuffi-
cient duration of ERT, which stresses the need for early in-
stitution of specific treatment in these patients. The leading
cause of death were respiratory system problems. Both pa-
tients who died in the ERT group had the severe phenotype
and died of complications associated with the underlying
disease (pneumonia and complications of anesthesia). The
higher mortality rate of Group A was clinically significant,
and the presence of more severely ill patients and the ab-
26 Dornelles et al.
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sence of ERT or other therapies in this group might help to
explain its higher mortality rate.
The length of follow-up was shorter in Group A than
in Group B, which can be explained by the greater number
of deaths in Group A. This, in turn, may have contributed to
the absence of specific treatment in this group. As
Laronidase is not included in the list of medicines provided
free of charge by the Brazilian government, most patients
with MPS I in the country can only secure access to it by
pursuing legal action; this may have been a contributing
factor to the delayed onset of ERT (in our sample, treatment
was initiated, on average, 1.5 years after diagnosis, and the
median time of follow-up for Group A was 11 months).
Disease severity may also have limited provision of ERT,
as most patients in Group A had the severe phenotype, and
there is some controversy in the literature regarding the use
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Table 3 - Enzyme replacement therapy for mucopolysaccharidosis type I: comparative analysis of clinical variables between T1 and T2 (n = 24).
No-ERT group (A) N = 9 ERT group (B) N = 15 Delta (%)*
T1 T2 T1 T2
Developmental delay 5 of 9 (55%) 7 of 9 (77%) 7 of 12 (58%) 9 of 12 (75%) -5%
Language delay 4 of 9 (44%) 5 of 9 (55%) 3 of 11 (27%) 5 of 11 (45%) +7%
Motor delay 4 of 10 (44%) 6 of 9 (66%) 4 of 12 (33%) 5 of 11 (41%) -14%
Joint contractures 5 of 6 (83%) 6 of 6 (100%) 13 of 15 (86%) 15 of 15 (100%) -3%
Seizures 0 of 9 (0%) 0 of 9 (0%) 0 of 14 (0%) 3 of 14 (21%) +21%
Splenomegaly 2 of 6 (33%) 3 of 6 (50%) 6 of 14 (42%) 4 of 14 (28%) -31%
Thoracolumbar gibbus deformity 3 of 6 (50%) 5 of 6 (83%) 10 of 14 (71%) 10 of 14 (71%) -33%
Hepatomegaly** 3 of 6 (50%) 5 of 6 (83%) 10 of 14 (71%) 6 of 14 (42%) -62%
Chronic medication use 4 of 9 (44%) 5 of 9 (55%) 4 of 14 (28%) 4 of 14 (28%) -11%
Death 0 of 9 (0%) 5 of 9 (55%) 0 of 15 (0%) 2 of 15 (13%) -42%
Surgical procedures 6 of 9 (66%) 2 of 9 (22%) 9 of 15 (60%) 5 of 15 (33%) +17%
Corneal opacities 4 of 6 (66%) 5 of 6 (83%) 8 of 14 (57%) 9 of 14 (64%) -10%
Reported:
Sleep apnea 2 of 8 (25%) 4 of 8 (50%) 5 of 15 (33%) 13 of 15 (86%) +28%
Hearing loss 2 of 9 (22%) 3 of 9 (33%) 4 of 12 (33%) 8 of 12 (66%) +22%
Hospital admission, all-cause 5 of 9 (55%) 6 of 9 (66%) 9 of 15 (60%) 4 of 15 (26%) -45%
Hospital admission, RTI 3 of 7 (42%) 3 of 7 (42%) 7 of 15 (46%) 3 of 15 (20%) -26%
LRTI** 2 of 7 (28%) 3 of 7 (42%) 7 of 15 (46%) 1 of 15 (6%) -40%
URTI 1 of 7 (14%) 0 of 7 (0%) 2 of 15 (13%) 2 of 15 (13%) +14%
*Delta = [(Group B at T2 - Group B at T1) - (Group A at T2 - Group A at T1)]. A delta of   20% between groups A and B was considered clinically rele-
vant.
**A delta of   40% was considered clinically relevant for these variables, due to the presence of a significant between-group difference at T1 (see
Methods section).
ERT, enzyme replacement therapy. RTI, respiratory tract infection. LRTI, lower respiratory tract infection. URTI, upper respiratory tract infection.
Table 2 - Comparison between Groups A and B at T1 (diagnosis) (n = 24).
Variable Group A* (n = 9) Group B* (n = 15) Clinically relevant difference
Median age, months (IQR) 36 (13-179) 33 (18-139) No
Male sex, n (%) 5 of 9 (55%) 8 of 15 (53%) No
Severe phenotype, n (%) 6 of 9 (66%) 4 of 15 (26%) Yes
Median age at symptom onset, months (IQR) 11 (3-36) 8 (3-18) No
Median weight, kg (IQR) 14.1 (9-36) 13.9 (11-30) No
Median height, cm (IQR) 92 (76-138) 98 (79-116) No
Median HC, cm (IQR) 51.3 (49-53) 51 (49-55) No
Hernia repair required, n (%) 2 of 9 (22%) 7 of 15 (46%) Yes
*Group A, no ERT between T1 and T2; Group B, ERT between T1 and T2.
ERT, enzyme replacement therapy; HC, head circumference; IQR, interquartile range.
of ERT in terminally ill patients. We should also point out
that the adhesion to the treatment was not evaluated in our
study; it is possible that many patients, for different reasons
(e.g., no easy access to the infusion center) have not re-
ceived all the infusions scheduled for the period.
We observed improvement in some efficacy out-
comes at T2, even though the duration of ERT in our sam-
ple cannot be considered long in view of the chronic nature
of MPS I. Nonetheless, we cannot attribute this improve-
ment solely to ERT, as there is a higher prevalence of se-
vere patients in group A (which are therefore likely to show
a worse outcome), whereas patients in group B also more
frequently received “adjunct” therapies. The higher con-
comitance of ERT and other therapies is an interesting find-
ing, which suggests that patients on ERT are also provided
with a better overall care or have more access to informa-
tion. Unfortunately, we were not able to perform any fur-
ther analysis regarding this variable since we did not have
any data in this respect at diagnosis.
Hospital admissions are frequent in patients with
MPS I, with respiratory tract infections being the leading
cause of hospitalization other than surgery (Vijay and
Wraith, 2005). The clinically relevant reduction in the rate
of hospital admission observed in Group B may be indica-
tive of a protective effect of ERT or respiratory physical
therapy, or even to a higher prevalence of the severe form in
Group A, as patients in Group A experienced an increase in
the number of hospitalizations. A clinically significant pro-
tective effect of ERT against lower respiratory tract infec-
tions is unreported in the literature.
Regarding clinical examination findings, patients in
the ERT group experienced a clinically significant reduc-
tion in the prevalence of hepatosplenomegaly, as expected
(Kakkis et al., 2001; Wraith et al., 2004, 2005, 2007;
Sifuentes et al., 2007; Clarke et al., 2009). It is worth stress-
ing that, as physical examination data at the time of ERT
onset were unavailable, improvement may have been un-
derestimated, as any deterioration between the time of diag-
nosis and the time of treatment onset will have gone unno-
ticed due to the study design. The fact that weight, height,
and head circumference could not be analyzed due to miss-
ing data reflects the challenges of performing retrospective
studies in which data collection is based on questionnaires.
Therefore, the association between anthropometric param-
eters and provision of ERT remains unclear, despite previ-
ous reports of a positive effect (Kakkis et al., 2001; Sifuen-
tes et al., 2007; Wraith et al., 2007; Clarke et al., 2009).
Both groups experienced a similar change in the prev-
alence of joint contractures (deterioration), although the
difference was not considered clinically relevant. Isolated
analysis of the progression of thoracolumbar gibbus defor-
mity could suggest that this manifestation progresses as the
disease does, but can be at least partially controlled by
ERT, as its frequency remained stable in the ERT group and
increased in the no-ERT group. However, this finding is
most probably due to the higher prevalence of the severe
form of the disease in the group A, since this form is more
frequently associated to the development of gibbus. There
is no information in the literature as to the effects of ERT on
gibbus deformity (Pastores and Meere, 2005).
Ophthalmic complaints are exceedingly common in
patients with MPS I, and corneal opacities affect virtually
all patients with the condition (Caruso et al., 1986; Neufeld
and Muenzer, 2001; Ashworth et al., 2006a,b; Pitz et al.,
2007; Fahnehjelm et al., 2010). The prevalence of corneal
opacities increased in both groups, despite ERT. There is
no consensus in the literature as to the effects of ERT on
this clinical manifestation (Kakkis et al., 2001; Pitz et al.,
2007; Sifuentes et al., 2007; Clarke et al., 2009).
The increase in the reported rate of sleep apnea and
hearing loss between T1 and T2 is probably attributable to
improved follow-up of patients with MPS I, particularly in
the ERT group, where this rate increase was clinically sig-
nificant. Again, this finding suggests that, once diagnosed,
many patients who began ERT also began other therapies,
which would have provided an add-on benefit to the effects
of ERT. The increased frequency of reported sleep apnea
and hearing loss may also be associated with a higher prev-
alence of the attenuated phenotype in group B, as patients
with the attenuated phenotype are usually free of cognitive
deficits and consequently able to express their complaints.
It is worth stressing that, as polysomnography and audio-
metry were unavailable to the majority of patients, the re-
ported presence of sleep apnea and hearing loss is not
sufficient to establish a diagnosis, which confirms that our
findings in relation to this parameter should be viewed with
caution. However, there have been reports in the literature
of a potential benefit of ERT on sleep apnea syndrome
(Kakkis et al., 2001; Wraith et al., 2005), but no reports on
hearing loss. Despite the lack of a biological explanation at
present, this finding could be an adverse event related to the
use of Laronidase.
Finally, there is a need for greater dissemination of
guidance and information on MPS I and provision of incen-
tives for the early diagnosis of patients with this condition.
ERT is still a high-cost, relatively novel treatment modality,
and many patients can only secure access to it by pursuing le-
gal action; furthermore, it must be combined with other ther-
apeutic interventions to achieve the optimal potential for
management of MPS I. Further studies focusing on the effect
of ERT on respiratory morbidity and overall mortality in pa-
tients with MPS I, and on other therapies, are needed.
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